Malignancy after renal transplantation: Incidence and role of type of immunosuppression

被引:88
作者
Tremblay, F
Fernandes, M
Habbab, F
Edwardes, MDD
Loertscher, R
Meterissian, S
机构
[1] McGill Univ, Ctr Hlth, Div Gen Surg, Montreal, PQ, Canada
[2] McGill Univ, Ctr Hlth, Div Transplantat, Montreal, PQ, Canada
[3] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada
关键词
cancers; renal transplants; cyclosporine; immunosuppression;
D O I
10.1245/ASO.2001.06.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer, particularly skin cancer and lymphoma, is a complication of posttransplantation immunosuppression. We investigated the characteristics of cancers in our renal transplant population, the role of type of immunosuppression on cancer incidence, and whether newer, more potent immunosuppressive agents produce cancers sooner after transplantation. Methods: The charts of patients who developed cancer after renal transplantation between 1958 and 2000 were reviewed. Statistical analyses were performed with the mid-P version of Fisher's exact test for 2 X 2 tables for incidence comparison of cancer and with Student's t-test for differences between mean times to cancer. Results: Between 1958 and 2000, 924 transplantations in 760 patients were performed. We found a cancer incidence of 12.2%. The most frequent cancers were skin and genitourinary. The overall mortality was 54%. We found an increased incidence of cancer in the group of patients in the cyclosporine era and for patients 45 years at transplantation. Cancer did not develop sooner in the cyclosporine group. Conclusions: The distribution of types of cancer was similar to that reported in the literature. The mortality rate was high. The incidence of cancer was higher in the cyclosporine era in patients greater than or equal to45 years at transplantation.
引用
收藏
页码:785 / 788
页数:4
相关论文
共 10 条
[1]   Malignancies in patients under long-term immunosuppression after kidney transplantation [J].
Behrend, M ;
Kolditz, M ;
Kliem, V ;
Oldhafer, KJ ;
Brunkhorst, R ;
Frei, U ;
Pichlmayr, R .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :834-835
[2]   CANCER RISK AFTER RENAL-TRANSPLANTATION IN THE NORDIC COUNTRIES, 1964-1986 [J].
BIRKELAND, SA ;
STORM, HH ;
LAMM, LU ;
BARLOW, L ;
BLOHME, I ;
FORSBERG, B ;
EKLUND, B ;
FJELDBORG, O ;
FRIEDBERG, M ;
FRODIN, L ;
GLATTRE, E ;
HALVORSEN, S ;
HOLM, NV ;
JAKOBSEN, A ;
JORGENSEN, HE ;
LADEFOGED, J ;
LINDHOLM, T ;
LUNDGREN, G ;
PUKKALA, E .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (02) :183-189
[3]   Risk factors for cancer in renal transplant recipients [J].
Danpanich, E ;
Kasiske, BL .
TRANSPLANTATION, 1999, 68 (12) :1859-1864
[4]  
Kasiske BL, 2000, J AM SOC NEPHROL, V11, pS1
[5]   RISK OF NEOPLASIA IN RENAL-TRANSPLANT PATIENTS [J].
LONDON, NJ ;
FARMERY, SM ;
WILL, EJ ;
DAVISON, AM ;
LODGE, JPA .
LANCET, 1995, 346 (8972) :403-406
[6]  
PENN I, 1991, TRANSPLANT P, V23, P1101
[7]  
Penn I, 1996, TRANSPLANT P, V28, P876
[8]  
SHEIL AGR, 1993, TRANSPLANT P, V25, P1383
[9]   Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation [J].
Sheil, AGR ;
Disney, APS ;
Mathew, TH ;
Livingston, BER ;
Keogh, AM .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :825-827
[10]  
Sheil AGR, 1996, TRANSPLANT P, V28, P1162